·SEC EDGARLow
Alfieri Michael purchased $6K of ALDX
Alfieri Michael (Principal Financial Officer) purchased 10,000 shares of Aldeyra Therapeutics, Inc. (ALDX) at $0.65 on 2026-11-11.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ALDX
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a biotechnology company developing therapies for immune-mediated diseases. Its pipeline includes RASP modulators ADX-248 and ADX-246, and late-stage candidates reproxalap and ADX-2191. Reproxalap is a topical treatment candidate for dry eye disease and allergic conjunctivitis. ADX-2191 is an intravitreal formulation of methotrexate being developed for primary vitreoretinal lymphoma and retinitis pigmentosa. Aldeyra has also completed proof-of-concept testing with oral RASP modulator ADX-629, which is no longer in development apart from potential investigator-sponsored trials in Sjögren-Larsson Syndrome. Aldeyra has no products approved for sale. It expects to generate money from product sales only if candidates receive regulatory approval, and intends to commercialize approved products directly or through collaborations. It has entered an option agreement with AbbVie concerning reproxalap, but AbbVie has not exercised the option as of February 27, 2026. Aldeyra is headquartered in Concord, Massachusetts.
Price · $ALDXvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 0
- Bearish
- 1
Insider · 30dAll trades →
- Buys
- $135K 2 txs
- Sells
- — 0 txs
DOUGLAS RICHARD1× · $129K
10b5-1 share of filings0%
Top stories · $ALDXMore →
·SEC EDGAR
DOUGLAS RICHARD purchased $129K of ALDX
DOUGLAS RICHARD purchased 200,000 shares of Aldeyra Therapeutics, Inc. (ALDX) at $0.64 ($0.13M total) on 2026-11-11.
·SEC EDGAR 8-K
Aldeyra Therapeutics, Inc. announced that the Company has formally requested that the Division of Ophthalmology of the U.S. Food and Drug Administration…
Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the Division of Ophthalmology (the “DO”) of the U.S. Food and Drug Administration (the “FDA”) submit a review jurisdiction
ALDX sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ALDX (Aldeyra Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent ALDX coverage spans insider activity, regulation and technology.
In the last 30 days, ALDX insiders filed 2 SEC Form 4 transactions — 2 purchases ($135K) and no sales. The most active reporter was DOUGLAS RICHARD with 1 filing.
What's driving ALDX
Insider purchase suggests confidence from the CFO, potentially supporting the stock price.
Insider buying can be read as mild positive sentiment, but the disclosed size is modest and lacks a new operational catalyst.
The regulatory path for ADX‑2191 in primary vitreoretinal lymphoma is now uncertain, likely delaying trials and increasing costs.
Regulatory setback likely weighs on the stock.
The FDA dispute filing is a positive catalyst that may improve regulatory outlook for reproxalap.
AlphAI scores every news story that mentions ALDX with an AI model for sentiment and relevance, and aggregates insider trades from Aldeyra Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ALDX
Score
Alfieri Michael purchased $6K of ALDX
Alfieri Michael (Principal Financial Officer) purchased 10,000 shares of Aldeyra Therapeutics, Inc. (ALDX) at $0.65 on 2026-11-11.
DOUGLAS RICHARD purchased $129K of ALDX
DOUGLAS RICHARD purchased 200,000 shares of Aldeyra Therapeutics, Inc. (ALDX) at $0.64 ($0.13M total) on 2026-11-11.
Aldeyra Therapeutics, Inc. announced that the Company has formally requested that the Division of Ophthalmology of the U.S. Food and Drug Administration…
Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the Division of Ophthalmology (the “DO”) of the U.S. Food and Drug Administration (the “FDA”) submit a review jurisdiction
EyeWorld Weekly, October 2, 2026
Rayner's RayOne Galaxy IOLs received FDA approval. Aldeyra plans to appeal FDA's rejection of reproxalap for dry eye disease. Sydnexis' SYD-101 for myopia will be reviewed at an FDA Advisory Committee meeting. Kodiak Sciences reported positive Phase 3 trial results for Zenkuda and KSI-501 in wet AMD. 4D Molecular Therapeutics began a Phase 3 trial for DME treatment with 4D-150. A study found a 16.1% increase in corneal transplants over 10 years, but supply-demand gap remains severe.
Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL
Aldeyra Therapeutics (ALDX) shares rose 13.79% after the company announced plans to submit a formal dispute resolution request to the FDA regarding its reproxalap program for dry eye disease. The FDA previously issued a Complete Response Letter citing insufficient evidence of efficacy. The move is seen as company-specific rather than sector-wide.
Rapid Dry Eye Relief With Investigational Reproxalap Drop
A pooled analysis of two trials found that reproxalap eye drops reduced dry eye symptoms more than a vehicle drop, with benefits seen in the first week. The most common side effect was irritation at the drop site. The study was funded by Aldeyra Therapeutics and published in Ophthalmology and Therapy.
Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update CONFERENCE CALL September 29, 2026 Nasdaq: ALDX
Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Other Events. Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update CONFERENCE CALL September 29, 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the
Aldeyra Therapeutics, Inc. (ALDX): Entry into a Material Definitive Agreement
Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On July 28, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) executed a lease agreement (the “Office Lease”) with Bradford Street, L.L.C. (“Bradford Street”) for approximately 4,067 square feet of office space lo
Aldeyra Therapeutics, Inc. (ALDX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001341235 Massachusetts 0001341235 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report
Brady Todd C purchased $418K of ALDX
Brady Todd C (President and CEO) purchased 250,000 shares of Aldeyra Therapeutics, Inc. (ALDX) at $1.67 ($0.42M total) on 2026-06-03.